Clinical Trial Update: Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Xenon for neuroprotection during Post-Cardiac Arrest Syndrome in comatose survivors of out-of-hospital cardiac arrest, curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-cardiac Arrest Syndrome

Drugs mentioned

• Xenon (xenon)

Snippet

Sponsor: Invero Pharma, Inc. | Conditions: Post-Cardiac Arrest Syndrome | Phase 3 | Status: NOT_YET_RECRUITING